To assess the therapeutic potential of AAV-β3AR gene therapy, we randomized WT mice to AAV9-hβ3AR or control AAV9-EGFP injection 8 weeks after supravalvular AS induction, by which time, mice have developed pronounced LVH and cardiac dysfunction (LVEF < 40%), and followed them for an additional 4 weeks (Fig. 5A). This evidence concerns the gene ADRB3 and aortic stenosis.